Woodline Partners’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
BBA
Woodline Partners's GPCR Position: Q3 2026 in Review
Woodline Partners increased its Structure Therapeutics (GPCR) stake by 0.05% in Q3 2026, buying an estimated $3.66K and bringing the position to 153,886 shares worth $4.81M. The position accounts for 0.01% of the portfolio, ranked #721.
Woodline Partners first reported a position in GPCR in Q1 2023 and has held it in 15 quarters since. The position peaked at $14.6M in Q3 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- Woodline Partners held 153,886 shares of Structure Therapeutics worth $4.81M as of Q3 2026.
- Woodline Partners bought 78 Structure Therapeutics shares in Q3 2026, an estimated $3.66K.
- Structure Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #721 holding.
- Woodline Partners first reported a position in Structure Therapeutics in Q1 2023 and has held it in 15 quarters since.
- Woodline Partners's Structure Therapeutics position peaked at $14.6M in Q3 2024.
- 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.